An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease
Phase of Trial: Phase II/III
Latest Information Update: 01 Nov 2018
Price : $35 *
At a glance
- Drugs Flortaucipir-F-18 (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease; Cognition disorders
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 02 Aug 2018 Planned End Date changed from 1 Aug 2017 to 31 Aug 2018.
- 02 Aug 2018 Planned primary completion date changed from 1 Aug 2017 to 31 Aug 2018.
- 04 Aug 2017 Status changed from active, no longer recruiting to completed.